COVAXIN approval a giant leap for innovation: Bharat Biotech CMD Krishna Ella
January 03, 2021
Krishna Ella, MD, Bharat Biotech×
The approval of COVAXIN for emergency use is a giant leap for innovation and novel product development in India, Krishna Ella, Chairman and Managing Director of Bharat Biotech, said.
Expressing delight on the DCGI-Central Standards Control Organization grant of permission for emergency use of its Covid-19 vaccine, the CMD of vaccine maker said, It is a proud moment for the nation and a great milestone in India s scientific capability. While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. COVAXIN has generated excellent safety data with robust immune responses to multiple viral proteins that persist.
India on Sunday granted emergency approval to Bharat Biotech s COVAXIN but faced questions after taking the step without publishing efficacy data for the homegrown coronavirus vaccine
India s approval of homegrown virus vaccine criticised over lack of data
03 Jan 2021 A health official and a volunteer (R) take part in a mock drill for vaccine delivery at a health centre in New Delhi. AFP
India on Sunday granted emergency approval to Bharat Biotech s COVAXIN but faced questions after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.
The news, announced by the drugs controller general of India (DCGI) who did not take questions, was hailed by Prime Minister Narendra Modi and his ministers as a success in India s self-reliance push.
The government also approved the use of a vaccine developed by AstraZeneca and Oxford University, which will be the lead vaccine in India s immunisation programme until other shots are approved.